HY-P0121_ReACp53_MCE
MCE-Anti-c-Myc-Magnetic-Beads-Manual-cn

2. 检测结果无条带? A. c-Myc 标签蛋白没有表达可能导致检测结果无条带,建议操作:a. 确保 目的蛋白带有 c-Myc 标签;b. 制备新鲜的裂解液;c. 使用恰当的蛋白酶抑 制剂 (如 MCE 的产品:HY-K0010,HY-K0011)。 B. 孵育时间不足可能导致检测结果无条带,建议延长孵育时间。 C. 裂解液中存在高浓度的 DTT、2-巯基乙醇或其他的还原剂等干扰物质, 建议选用合适的裂解液。
包装 1 mL 1 mL × 5
2 产品概述
MCE Anti-c-Myc Magnetic Beads 由高质量的鼠源 IgG1 单克隆抗体与氨基 磁珠共价偶联制备,具有较高的 c-Myc 标签融合蛋白加载容量 (>1 mg蛋 白/mL),可用于细菌和哺乳动物细胞裂解物以及体外表达系统中 c-Myc 标 记蛋白的免疫沉淀 (IP) 实验。本产品可以通过磁力架 (MCE 产品目录号: HY-K0200)或自动分离仪器分离,实验便捷有效。本产品蛋白荷载量高, 特异性强,也可用于免疫共沉淀 (Co-IP) 和小量的蛋白质纯化实验。
MCE 中国 400-820-3792
电话: 021-58955995
传真: 021-53700325
Email: tech@
Inhibitors, Agonists, Screening Libraries
1. 磁珠预处理 混悬 Anti-c-Myc Magnetic Beads,取 20 μL 磁珠,置于 1.5 mL EP 管中, 加入 500 μL 洗涤缓冲液,充分混悬,置于磁力架上磁性分离,弃上清。重 复以上洗涤步骤 2 次。 2. 样品的结合 在上述分离得到的磁珠中加入 500 μL 细胞裂解液,充分混悬,置于翻转混 合仪孵育,室温孵育 2 小时或者 4℃ 条件下孵育过夜。置于磁力架上磁性
2X M5 HiPer SYBR Premix EsTaq plus (with Tli RNase

2X M5 HiPer SYBR Premix EsTaq plus (with Tli RNaseH)使用说明书产品名称单位货号2X M5 HiPer SYBR Premix EsTaq plus (with Tli RNaseH) 50 μl反应× 40 次MF788-T2X M5 HiPer SYBR Premix EsTaq plus (with Tli RNaseH) 50 μl反应× 200 次MF788-012X M5 HiPer SYBR Premix EsTaq plus (with Tli RNaseH) 50 μl反应× 400 次MF788-02【储存条件】长期保存,请置于-20˚C,有效期24个月。
经常使用,可置于4˚C保存至少六个月。
【产品简介】本产品采用Sybrgreen嵌合荧光法进行荧光定量的专用试剂。
制品中含有荧光定量反应的最适浓度Sybrgreen,是一种2×浓度的预混试剂,进行实验时,PCR反应液的配制十分方便简单。
制品中使用了antiTaq抗体的Hot Start法用DNA聚合酶,与荧光定量反应适合Buffer组合,可以有效抑制非特异性的PCR扩增,大大提高PCR的扩增效率,可以进行高灵敏度的荧光定量扩增反应。
本产品Buffer 经过改良,使反应特异性比SybrGreenPremix Ex Taq (withTli RNaseH)(货号MF787)更高。
另外,本产品中添加了Tli RNaseH (耐热性RNaseH),以cDNA作为模板进行PCR反应时,可以很好地抑制由于cDNA中残存mRNA 对PCR反应造成的阻害作用。
适合于快速荧光定量扩增反应,可以在宽广的定量区域内得到良好的标准曲线,对靶基因进行准确定量、检测,重复性好,可信度高。
【产品组份】MF788-T MF788-012x M5 HiPer SYBR Premix EsTaq plus (withTli RNaseH) * 1.0 ml 5x1mlROX Reference Dye(50×)** 40μl 200μlROX Reference Dye II(50×)** 40μl200μl*由以下组分预混而成:EsTaq plus,dNTP Mixture,Mg2+,Tli RNaseH,Sybrgreen。
HY-15664_Bivalirudin Trifluoroacetate_MCE

Data SheetBIOLOGICAL ACTIVITY:Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.IC50 Value:Target: thrombinin vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor)effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) [1]. In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l [2]. Bivalirudin⁻facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO⁻mediated redox modifications [3].in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats [4]. Three animals in the 500⁻mg/kg/24 h group, and 7 animals in the 2000⁻mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent [5].Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4References:[1]. Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Acta Pol Pharm. 2009 May⁻Jun;66(3):235⁻42.[2]. Xu Y, Wu W, Wang L, Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis. 2013 Apr;24(3):332⁻8.[3]. Rudolph V, Rudolph TK, Schopfer FJ, Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008Nov;327(2):324⁻31.[4]. Zhang R, Huang Y, Zhang M, Bivalirudin Utilization in Rats Undergoing Cardiopulmonary Bypass: Preventing the Increase of Antiheparin/Platelet Factor 4Antibody in Perioperative Period. Clin Appl Thromb Hemost. 2012 Aug 21. [Epub ahead of print][5]. Gleason TG, Chengelis CP, Jackson CB, A 24⁻hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May⁻Jun;22(3):195⁻206.Product Name:Bivalirudin (Trifluoroacetate)Cat. No.:HY-15664CAS No.:128270-60-0Molecular Formula:C 100H 138DF 3N 24O 35Molecular Weight:2295.32Target:ThrombinPathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 31 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USACertificate of AnalysisPHYSICAL AND CHEMICAL PROPERTIESMolecular Formula:C 100H 138DF 3N 24O 35Molecular Weight:2295.32Storage:Powder -20°C 3 years 4°C 2 years In solvent-80°C 6 months -20°C1 monthChemical Structure:ANALYTICAL DATAAppearance:White to off-white (Solid)1H NMR Spectrum:Consistent with structure Purity (NMR):>98.0%Conclusion:The product has been tested and complies with the given specifications.Product Name:Bivalirudin (Trifluoroacetate)Cat. No.:HY-15664CAS No.:128270-60-0Batch No.:09618Chemical Name:L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USASafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Bivalirudin (Trifluoroacetate)Catalog No. :HY-15664CAS No. :128270-60-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:BivalirudinFormula:C100H138DF3N24O35Molecular Weight:2295.32CAS No. :128270-60-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAppm (f1)0.01.02.03.04.05.06.07.08.09.08.1818.1728.1648.1628.1598.0718.0678.0558.0538.0538.0478.0448.0428.0378.0338.0297.9437.9427.4197.4177.4147.3237.3047.2186.9976.6256.6044.4364.2794.2214.2084.2054.1904.1874.1864.1844.1713.7513.3483.3453.3412.9352.9342.9322.9312.9282.9242.6732.6692.6662.6652.5052.5002.4952.1571.8131.8021.7991.7971.7801.7791.7401.7381.7381.7371.7151.7021.6991.6961.6951.68915150214980.8690.815-0.0032.03417.4801.4602.5511.1643.5318.332 5.22410.18210.1064.1899.54021.8987.34610.0471.4155.6736.470Date:1 Jun 2015Document's Title:Catalog No: HY-15664 Batch#09618Spectrum Title:HY_CPK2015-526-09618Frequency (MHz):(f1) 399.741Original Points Count:(f1) 32768Actual Points Count:(f1) 65536Acquisition Time (sec):(f1) 4.0894Spectral Width (ppm):(f1) 20.045 Pulse Program:UnknownTemperature: 20Number of Scans: 8Acq. Date: May 26 2015D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH TFASample ID:CPK2015-526-09618,Catalog No: HY-15664 Batch#09618,DMSO。
HYQ spin 无内毒素质粒中提试剂盒- HG111

HYQspin TM无内毒素质粒中提试剂盒VER:1.0试剂盒组成Catalog#HG11202HG11203规格1025离心柱102515mL收集管2050 Buffer B1*30mL70mL Buffer B230mL70mL Buffer B415mL30mL Buffer RES60mL150mL Buffer KS60mL150mL Buffer FES15mL40mLRNase A(50mg/mL)10mg(200µL)(10µL)25mg(500µL)说明书11 *使用前将提供的所有RNase A全部加入Buffer B1中,4o C贮存。
产品介绍:本试剂盒采用Qbiosource公司自主开发吸附系统,通过特殊的缓冲液RES高效、快速地去除大肠杆菌裂解液中所含的内毒素,并用新型硅基质膜可逆专一吸附质粒DNA,继而用Buffer KS和乙醇除去蛋白和其他杂质,最后用Buffer FES把核酸洗脱下来的方法快速纯化质粒DNA。
纯化的质粒DNA最大限度地去除了内毒素污染,可直接用于转染各种内毒素敏感性细胞株,原代细胞或者直接进行微注射等下游应用。
Feature样品15~50mL大肠杆菌类型离心柱收益率高拷贝数的质粒100~200µg DNA操作离心应用内毒素敏感性细胞株,原代细胞或直接进行微注射等储存条件:本试剂盒自购买之日起,可以保存12个月。
其中RNase A试剂应保存在4°C,其他组分室温(22-25°C)保存。
实验准备:请按照说明书准备所需的试剂和耗材,熟悉每一步操作和注意下列事项:□RNase A:50mg/mL.50mg/mL的RNA酶,室温下可稳定贮藏半年,长期贮藏请置于4℃保存。
使用前将提供的所有RNase A离心后加入Buffer B1,然后将加了RNase A的Buffer B1置于4°C保存。
□Buffer B2在低于室温时会沉淀,如有浑浊现象,使用前请于50°C 左右水浴加热至沉淀完全溶解,溶液澄清。
2-甲氧基乙氧基甲基氯结构

2-甲氧基乙氧基甲基氯结构
2-甲氧基乙氧基甲基氯是一种有机化合物,其化学式为C5H11ClO2。
它的结构中含有一个氯原子和三个氧原子,分别连接在一个碳原子上。
下面将详细介绍2-甲氧基乙氧基甲基氯的性质和应用。
2-甲氧基乙氧基甲基氯是一种有机氯化合物。
有机氯化合物广泛存在于生物体内和环境中,是一类重要的化学物质。
这类化合物具有较高的化学稳定性和生物活性,因此在医药、农药、化工等领域有着广泛的应用。
2-甲氧基乙氧基甲基氯具有一定的溶解性。
在常见的溶剂中,2-甲氧基乙氧基甲基氯能够较好地溶解,使其具有一定的可操作性。
这种溶解性使得2-甲氧基乙氧基甲基氯在化学合成和实验中有着广泛的应用。
2-甲氧基乙氧基甲基氯还具有一定的稳定性。
在适当的条件下,2-甲氧基乙氧基甲基氯具有较高的热稳定性和化学稳定性,不易发生分解或降解反应。
这种稳定性使得2-甲氧基乙氧基甲基氯能够在一定的温度和压力下稳定存在,并能够在合成反应中发挥作用。
2-甲氧基乙氧基甲基氯在医药和农药领域有着重要的应用。
在医药领域,2-甲氧基乙氧基甲基氯可以作为一种重要的中间体,用于合成各种药物。
在农药领域,2-甲氧基乙氧基甲基氯可以作为一种杀虫剂,用于防治农作物上的害虫。
2-甲氧基乙氧基甲基氯是一种有机氯化合物,具有一定的溶解性和稳定性。
它在医药和农药领域有着广泛的应用。
随着科学技术的不断发展,对2-甲氧基乙氧基甲基氯的研究和应用还将进一步深入,为人们的生活和工作带来更多的便利和效益。
MIRA-1_野生型p53构象细胞功能的恢复剂_72835-26-8_Apexbio

生通路:
p53
产品描述:
Restores wild-type conformation, function and DNA binding activity to mutant p53. Induces p53 transcriptional transactivation of p21, MDM2 and PUMA, and promotes tumor cell death by apoptosis in a mutant p53-dependent manner in vitro (IC50 = 10μM).
CCC(=O)OCN1C(=O)C=CC1=O
Soluble in DMSO > 10 mM
Store at 4°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
参考文献:
特别声明
产品仅用于研究, 不针对患者销售,望谅解。 每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定 的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的,运输温度不同于长 期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后,按照 产品说明书上的要求进行储存。
Alpha-1-Proteinase Inhibitors产品说明

Alpha-1-Proteinase Inhibitors:Aralast NP®; Glassia®; Prolastin®-C; Zemaira®(Intravenous)Document Number: IC-0052 Last Review Date: 04/06/2021Date of Origin: 01/01/2012Dates Reviewed: 12/2011, 02/2013, 08/2013, 06/2014, 06/2015, 01/2016, 10/2016, 03/2017, 09/2017, 12/2017, 03/2018, 06/2018, 04/2019, 04/2020, 04/2021I.Length of AuthorizationCoverage will be provided for 12 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC Unit]:∙Aralast NP 1 g/50 mL: 7 vials per week∙Aralast NP 0.5 g/25 mL: 1 vial per week∙Glassia 1 g/50 mL: 7 vials per week∙Prolastin-C 1 g/20 mL: 7 vials per week∙Prolastin-C Liquid 1g/20 mL: 7 vials per week∙Zemaira 1 g/20 mL: 3 vials per week∙Zemaira 4 g/76 mL: 1 vial per week∙Zemaira 5 g/95 mL: 1 vial per weekB.Max Units (per dose and over time) [HCPCS Unit]:∙700 billable units every 7 daysIII.Initial Approval Criteria1-6,8,9,12•Patient is at least 18 years of age; ANDUniversal Criteria•Patient is not a tobacco smoker; AND•Patient is receiving optimal medical therapy (e.g., comprehensive case management, pulmonary rehabilitation, vaccinations, smoking cessation, self-management skills, etc.);AND•Patient does not have immunoglobulin-A (IgA) deficiency with antibodies against IgA;ANDEmphysema due to alpha-1-antitrypsin (AAT) deficiency †, Ф(applies only to Prolastin-C)•Patient has an FEV1 in the range of 30-65% of predicted; AND•Patient has alpha-1-antitrypsin (AAT) deficiency with PiZZ, PiZ (null), or Pi (null, null) phenotypes; AND•Patient has AAT-deficiency and clinical evidence of panacinar/panlobular emphysema;AND•Patient has low serum concentration of AAT ≤ 57 mg/dL or ≤ 11 µM/L as measured by nephelometry† FDA Approved Indication(s); Ф Orphan DrugIV.Renewal Criteria1-6,8,9Authorizations can be renewed based on the following criteria:•Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc.identified in section III; AND•Disease response with treatment as defined by elevation of AAT levels above baseline, substantial reduction in rate of deterioration of lung function as measured by percentpredicted FEV1, or improvement in CT scan lung density; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include severe hypersensitivity reactions, etc.V.Dosage/Administration1-5VI.Billing Code/Availability InformationHCPCS Code & NDC:VII.References1.Glassia [package insert]. Lexington, MA; Baxalta US Inc.; June 2017. Accessed March2021.2.Zemaira [package insert]. Kankakee, IL; CSL Behring LLC; April 2019. Accessed March2021.3.Aralast NP [package insert]. Lexington, MA; Baxalta US Inc.; December 2018. AccessedMarch 2021.4.Prolastin-C Liquid [package insert]. Research Triangle Park, NC; Grifols Therapeutics,Inc.; August 2018. Accessed March 2021.5.Prolastin-C [package insert]. Research Triangle Park, NC; Grifols Therapeutics, Inc.; June2018. Accessed March 2021.6.American Thoracic Society/European Respiratory Society Statement: Standards for theDiagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. AmericanThoracic Society; European Respiratory Society. Am J Respir Crit Care Med. 2003 Oct1;168(7):818-900.7.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for thediagnosis, management, and prevention of chronic obstructive pulmonary disease. GlobalInitiative for Chronic Obstructive Lung Disease (GOLD); 2019.8.Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami). 2016; 3(3):668-682.9.Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targetedtesting and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.Can Respir J. 2012;19(2):109-16.10.Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safetyand tolerability of a new α1-proteinase inhibitor, Zemaira. COPD. 2006;3:17–23.11.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for thediagnosis, management, and prevention of chronic obstructive pulmonary disease. GlobalInitiative for Chronic Obstructive Lung Disease (GOLD); 2020.12.Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement:diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J2017; 50.Appendix 1 – Covered Diagnosis CodesAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: /medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A。
MCE_Protein_AG_Magnetic_Beads_Manual_cn

MedChem Express
Protein A/G Magnetic Beads
1
包装清单
产品编号 HY-K0202-1 mL HY-K0202-5 mL 产品名称 Protein A/G Magnetic Beads Protein A/G Magnetic Beads 包装 1 mL 1 mL × 5
4
操作说明
推荐缓冲液 (自备) 结合/洗涤缓冲液 洗脱缓冲液 PBST : 1× PBS + 0.5% Triton X-100, pH 7.4 0.15 M Glycine, 0.5% Triton X-100 or Tween-20, pH 2.5-3.1
(1) 抗体预处理:使用结合/洗涤缓冲液将抗体稀释至终浓度为 5-50 μg/mL 。 (2) 抗体-磁珠结合:将稀释好的 400 μL 抗体加入步骤 2 处理好的磁珠中, 充分混悬,置于翻转混合仪孵育 (室温,30 mins;4°C,2 hours),磁性分 离,收集磁珠,上清液收集于新的 EP 管中,以备后续使用。 (3) 洗涤:加入 400 μL 结合/洗涤缓冲液,充分混悬磁珠,磁性分离,弃上 清;重复洗涤 4 次。 注:结合过程中,磁珠可能会出现聚团或呈片状,属于正常现象,不会影 响实验结果。 4. 抗原与抗体-磁珠复合物结合 (1) 抗原-抗体-磁珠复合物结合:加入 400 μL 步骤 1 准备的抗原样品,充分 混悬,置于翻转混合仪孵育 (室温,30 mins;4°C,2 hours) ,磁性分离, 弃上清。 (2) 洗涤:使用 400 μL 结合/洗涤缓冲液 充分重悬磁珠,磁性分离,弃上清; 重复洗涤 4 次。
3
产品特性
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Data SheetBIOLOGICAL ACTIVITY:ReACp53 is cell⁻penetrating peptide, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high⁻grade serous ovarian carcinomas (HGSOC).target: p53 amyloid formationIn vitro: ReACp53 rescues p53 transcription of target genes and restores apoptosis.In vivo:ReACp53 halts progression and shrinks tumors bearing aggregation⁻prone p53.References:[1]. Soragni A et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11;29(1):90⁻103.Product Name:ReACp53Cat. No.:HY-P0121Molecular Formula:C 108H 206N 52O 24Molecular Weight:2617.12Target:Others Pathway:Others Solubility:DMSOCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USACertificate of AnalysisPHYSICAL AND CHEMICAL PROPERTIESMolecular Formula:C 108H 206N 52O 24Molecular Weight:2617.12Storage:Powder-20°C 3 years 4°C 2 years In solvent -80°C6 months -20°C1 monthChemical Structure:ANALYTICAL DATAAppearance:White to off-white (Solid)HPLC:Consistent with structure MS:Consistent with structure Purity (HPLC):99.65%Conclusion:The product has been tested and complies with the given specifications.Product Name:ReACp53Cat. No.:HY-P0121Batch No.:21408Chemical Name:H-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Ile-Leu-Thr-Arg-Ile-Thr-Leu-Glu-OHCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USASafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :ReACp53Catalog No. :HY-P0121CAS No. :None1.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:ReACP53Formula:C108H206N52O24Molecular Weight:2617.12CAS No. :None4. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。